Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Globe Newswire•12/10/2026•16:00 ET
0
Key Highlights
- ➤Aficamten significantly improved BEAP-RS versus placebo at 36 weeks.
- ➤Aficamten met the primary endpoint, improving peak VO₂ by 1.8 mL/kg/min.
- ➤Aficamten reduced NT-proBNP by 30% versus placebo at 36 weeks.
- ➤Cytokinetics plans to submit a supplemental New Drug Application this quarter.
Expert Statements
Stephen Heitner, Chief Medical Officer of Cytokinetics
“These additional analyses from ACACIA-HCM add to the body of evidence supporting the overall benefit-risk profile of aficamten in patients with nHCM.”
Stephen Heitner, Chief Medical Officer of Cytokinetics
“The current CPET analysis demonstrates significant improvement in a clinically relevant and novel metric of global exercise performance, while additional data provide insights into dose titration and reinforce our confidence in the safety and treatment effect of aficamten in nHCM.”
Stephen Heitner, Chief Medical Officer of Cytokinetics
“We plan to submit a supplemental New Drug Application to the FDA this quarter.”
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, AZ.
Get started
Create a free account to read the full story.